Based on these therapies, commonly used small-molecule immune drugs mainly include resiquimod [7,8], nivolumab [9], pembrolizumab [10,11], atezolizumab [12,13], camrelizumab [14,15], and ipilimumab [16,17], which have made remarkable progress in activating toll-like receptors (TLRs) TLR7 and TLR8 receptors, blocking the PD-1/PD-L1 pathway, and opening a new era of tumor therapy. The gene discussed is CD274; the disease is neoplasm.